328.26 USD
↘ 0.87 (0.26%)AT CLOSE (11:59 AM EDT)
Amgen Inc
AMGNNASDAQ • USD
328.48
↗ 0.22 (0.07%)
POST MARKET (AS OF 04:22 PM EDT)
Post Market
AS OF 04:22 PM EDT
328.48
↗ 0.22 (0.07%)
Market: OPEN
Open?$326.17
High?$329.46
Low?$322.30
Prev. Close?$329.13
Volume?1.5M
Avg. Volume?2.6M
VWAP?$327.42
Rel. Volume?0.60x
Bid / Ask
Bid?$309.70 × 40
Ask?$344.32 × 40
Spread?$34.62
Midpoint?$327.01
Valuation & Ratios
Market Cap?177.6B
Shares Out?539.7M
Float?537.5M
Float %?99.6%
P/E Ratio?22.77
P/B Ratio?19.33
EPS?$14.45
Dividend?2.93%
Ex-Dividend?N/A
AMGN is currently priced at $328.48. Technicals currently rate "Sell" while our fundamental analysis reads "Neutral". Key drivers include a concerning Altman Z-Score in the distress zone, a strong Piotroski F-Score of 7/9, exceptional Return on Equity (84.9%) and a bullish Golden Cross on the moving averages. AMGN is fairly valued relative to its sector peers based on current multiples.
Technical & fundamental data as of Jun 2, 2026.
News
Profile
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Themes
Employees
31.5K
Market Cap
177.6B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
1983-06-17
Address
ONE AMGEN CENTER DRIVE
THOUSAND OAKS, CA 91320
Phone: (805)447-1000
THOUSAND OAKS, CA 91320
Phone: (805)447-1000
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?88
Z-Score?28
Momentum?87
Short Sent.?63
Piotroski F-Score?7/9Strong
Altman Z-Score?1.77Distress
Confidence?66%Moderate
Short InterestModerate
Short % of Float?2.29%Low
Short Interest?12.3M
Days to Cover?4.3
Free Float537.5M
Avg Daily Volume2.9M
Settlement Date2026-05-15
Financial Health
Current Ratio?1.26Adequate
Quick Ratio?1.01Adequate
Cash Ratio?0.48Low
Debt/Equity?6.24High
ValuationFAIRLY VALUEDvs 10 peers + S&P 500
Score61/100
P/E?22.8FAIR▾
Peers70
S&P55
P/B?19.33HIGH▾
Peers20
S&P8
P/S?4.77FAIR▾
Peers73
S&P31
P/FCF?20.7FAIR▾
Peers44
S&P53
EV/EBITDA?14.4FAIR▾
Peers70
S&P54
EV/Sales?5.99FAIR▾
Peers55
S&P28
Returns & Efficiency
ROE?84.9%STRONG▾
Peers100
S&P97
ROA?8.4%STRONG▾
Peers60
S&P68
Cash Flow & Enterprise
FCF?$8.6B
Enterprise Value?$222.9B
Fundamentals ratios updated end of day